Inspire Medical Systems Inc

Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inspire Medical Systems achieves first profitable quarter, eyes international growth

Inspire Medical Systems reported a strong performance in Q4 2022, achieving its first profitable quarter and significant revenue growth. The company's focus on enhancing patient outcomes, expanding internationally, and optimizing operational efficiency positions it for continued success.
While challenges with the supply chain were addressed, the company needs to remain vigilant in managing disruptions and addressing analyst concerns to ensure sustained growth. Opportunities in product demand, market expansion, and operational enhancements offer avenues for further development.
Overall, Inspire Medical Systems' strategic initiatives, strong financial performance, and commitment to innovation indicate a positive outlook for future growth and market expansion. The company's focus on driving utilization, improving patient outcomes, and maintaining operational efficiency bodes well for its long-term success.

Inspire Medical Systems Inc reports stellar Q1 performance and eyes global growth opportunities

Inspire Medical Systems Inc delivered robust financial results in Q1 2023, driven by revenue growth and international expansion.
The company's strategic focus on innovation, customer engagement, and therapy adoption positions it well for future success.
Challenges in competition, operational efficiency, and market dynamics require careful navigation, but opportunities for growth and innovation abound.
Overall, Inspire's performance reflects a company poised for continued expansion and impact in the medical technology sector.

Inspire Medical Systems reports robust Q2 growth and eyes global expansion

Inspire Medical Systems delivered strong financial performance in Q2, with revenue growth and margin improvement.
The company's strategic focus on expanding globally, enhancing operational efficiency, and product innovation positions it for future success.
While facing challenges in managing expenses and market mix, Inspire Medical Systems is well-positioned to capitalize on growth opportunities.
Overall, the company's performance, strengths, and strategic initiatives indicate a positive outlook for future growth and market expansion.

Inspire Medical Systems achieves record patient milestone and revenue growth

Inspire Medical Systems reported strong performance in Q3 2023, with notable revenue growth and patient milestones.
Despite challenges with prior authorizations and EU MDR approval delays, the company remains focused on growth and stakeholder value.
Opportunities for expansion with payers and new programs signal a positive outlook for future growth and market reach.
Efforts to streamline processes, educate centers, and drive efficiencies position the company for continued success in the sleep apnea treatment market.

Inspire Medical Systems posts robust Q4 results, eyes global expansion

Inspire Medical Systems reported strong Q4 performance, focusing on growth, profitability, and patient outcomes.
Challenges include market competition, revenue declines in certain regions, and securing reimbursements.
Opportunities lie in expanding utilization rates, market growth in Europe and Asia, and collaborations for increased patient flow.

Inspire Medical Systems Inc reports robust Q1 performance and growth outlook

Inspire Medical Systems Inc's Q1 2024 performance reflects strong revenue growth, improved net loss metrics, and a positive outlook for profitability and revenue expansion in 2024.
The company's strengths lie in its patient-centric approach, innovative product pipeline, and strategic growth initiatives, while challenges include financial performance, competitive landscape, and market penetration.
Opportunities abound in expanding patient qualification, market awareness, and operational efficiency, positioning Inspire for sustained growth and market leadership in the healthcare sector.

Inspire Medical Systems reports strong Q2 performance and growth outlook

Inspire Medical Systems demonstrated robust financial performance, marked by revenue growth and improved profitability.
Strategic initiatives to enhance patient experience and expand market reach position the company for sustained growth.
While facing challenges related to rising expenses, the company's focus on operational efficiency and growth opportunities remains strong.

Inspire Medical Systems reports strong Q3 earnings and growth outlook

Inspire Medical Systems Inc demonstrated robust financial performance in Q3 2024, with revenue and net income showing significant growth.
Despite challenges like revenue headwinds in Q4, the company's focus on innovation and capacity expansion presents growth opportunities.
The upcoming launch of the Inspire V system and efforts to streamline patient access highlight Inspire's commitment to driving future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inspire Medical Systems, Inc. (NYSE:INSP ) Q3 2022 Earnings Conference Call November 1, 2022 5:00 PM ET Company Participants Ezgi Yagci - IR Tim Herbert - President & CEO Rick Buchholz - CFO Conference Call Participants Travis Steed - Bank of America Jonathan Block - Stifel Robbie Marcus - JP Morgan Larry Biegelsen - Wells Fargo Adam Maeder - Piper Sandler Chris Pasquale - Nephron Research Rich Newitter - Truist Phil Coover - Goldman Sachs Suraj Kalia - Oppenheimer Operator Good afternoon. My name is Dalen, and I'll be your conference operator today.

Inspire Medical Systems, Inc. (INSP) Q3 2022 Earnings Call Transcript

Inspire (INSP) delivered earnings and revenue surprises of 20% and 14.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Inspire Medical Systems (INSP) Reports Q3 Loss, Tops Revenue Estimates

Inspire Reports Year-over-Year Revenue Growth of 77% in the Third Quarter Inspire Reports Year-over-Year Revenue Growth of 77% in the Third Quarter

Inspire Medical Systems, Inc. Announces Third Quarter 2022 Financial Results and Updates 2022 Outlook

A 3-5 month prospect from here of Inspire Medical Systems, Inc. share prices could reasonably range from a $166 low to a $210 high from its present price of $175, a +20.8% gain. 39 positions like today's in the past 5 years of 1042 market days produced average net gains at 23.4% each during 31 market days (6 weeks) or +450% CAGR.

Inspire Medical Systems: Sleep Apnea Equipment - Today's Best Stock Buy

Inspire (INSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Inspire (INSP) Soars 7.9%: Is Further Upside Left in the Stock?

Axonics ModulationTechnologies Inc

Pulmonx

Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Inc. (INSP), Axonics (AXNX), and Pulmonx Corporation (LUNG) are expected to gain on rising demand for telehealth.

3 Medical Info System Stocks to Gain on Rising Demand for Digital Health

This investment choice is based on the market's judgment that investors have favorable odds to see a +20% gain in the next few months from the stock's ownership. How do we believe that can happen? Smart money is betting that it will. Not only the market-active institutional investor-buyers seeing continued recovery, but also the hedging speculator-insurance providers.

Inspire Medical Systems: Sleep Apnea Value Delivery Pocket

The consensus price target hints at a 46.4% upside potential for Inspire (INSP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Inspire (INSP) Could Rally 46%: Here's is How to Trade

MINNEAPOLIS, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today key updates from the International Surgical Sleep Society (ISSS) and American Academy of Otolaryngology (AAO-HNSF) meetings which took place in Philadelphia September 9-14th.

Inspire Medical Systems, Inc. Announces Updates from International Surgical Sleep Society and American Academy of Otolaryngology – Head and Neck Surgery Meetings

Inspire (INSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Inspire (INSP) Stock Jumps 5.6%: Will It Continue to Soar?

MINNEAPOLIS, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced the appointment of Ezgi Yagci as Vice President of Investor Relations, effective August 15, 2022.

Inspire Medical Systems, Inc. Announces Appointment of Ezgi Yagci as Vice President of Investor Relations

MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today the pricing of an underwritten public offering of 1,000,000 shares of its common stock, at a public offering price of $215.00 per share, before underwriting discounts and commissions. In addition, Inspire has granted the underwriter a 30-day option to purchase up to an additional 150,000 shares of its common stock at the public offering price, less underwriting discounts and commissions, to cover sales by the underwriter in the initial offering of the shares or in the open market. All of the shares in the offering are to be sold by Inspire. The offering is expected to close on August 16, 2022, subject to customary closing conditions.

Inspire Medical Systems, Inc. Announces Pricing of Offering of Common Stock

MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today the commencement of a proposed public offering of 1,000,000 shares of its common stock. Inspire also expects to grant the underwriter a 30-day option to purchase up to an additional 150,000 shares of its common stock to cover sales by the underwriter in the initial offering of the shares or in the open market. All of the shares in the proposed offering are to be sold by Inspire.

Inspire Medical Systems, Inc. Announces Proposed Offering of Common Stock

Inspire Medical Systems reported Q2 FY22 earnings yesterday with upside versus consensus in revenue and EPS. The company upgraded FY22 revenue guidance but narrowed its guidance on gross margin for the year.

Inspire Medical: Valuations Fair And Reasonable Post Q2 Earnings

Inspire Medical Systems, Inc. (NYSE:INSP ) Q2 2022 Results Conference Call August 2, 2022 5:00 PM ET Company Participants Megan Rowekamp - Investor Relations Tim Herbert - President and Chief Executive Officer Rick Buchholz - Chief Financial Officer Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JP Morgan Travis Steed - Bank of America Rich Newitter - Truist Jonathan Block - Stifel Amit Hazan - Goldman Sachs Chris Pasquale - Nephron Research Adam Maeder - Piper Sandler Michael Polark - Wolfe Research Operator Good afternoon. My name is Dylan, and I'll be your conference operator today.

Inspire Medical Systems, Inc. (INSP) CEO Tim Herbert on Q2 2022 Results - Earnings Call Transcript

Inspire Reports Year-over-Year Revenue Growth of 73% in the Second Quarter Inspire Reports Year-over-Year Revenue Growth of 73% in the Second Quarter

Inspire Medical Systems, Inc. Announces Second Quarter 2022 Financial Results and Updates 2022 Outlook

Company adds further expertise in human capital strategy and medical device industry R&D, regulatory affairs and commercialization Company adds further expertise in human capital strategy and medical device industry R&D, regulatory affairs and commercialization

Inspire Medical Systems, Inc. Announces Appointment of Two New Independent Directors to its Board

MINNEAPOLIS, July 06, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced that the United States Food and Drug Administration (FDA) has approved additional magnetic resonance imaging (MRI) scan conditions for use with Inspire therapy. This full-body MRI approval expands the Inspire use labeling that previously allowed only head, neck, and extremity MRI scans. Most importantly, this approval is retroactive, applying to all patients with the Inspire IV neurostimulator device, introduced in 2018, already in place.

Inspire Medical Systems, Inc. Announces FDA Approval of Expanded, Full-Body MRI Compatibility with Inspire Therapy

MINNEAPOLIS, July 05, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2022 after the close of trading on Tuesday, August 2. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Inspire Medical Systems, Inc. to Report Second Quarter 2022 Financial Results on August 2, 2022

MINNEAPOLIS, June 06, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will be presenting at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 at the Terranea Resort in Rancho Palos Verdes, CA.

UPDATE — Inspire Medical Systems, Inc. to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Inspire Medical Systems, Inc. to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Highlighted by a robust clinical program and the introduction of Inspire SleepSync™ Digital Health enabled by a new Bluetooth® Patient Remote Highlighted by a robust clinical program and the introduction of Inspire SleepSync™ Digital Health enabled by a new Bluetooth® Patient Remote

Inspire Medical Systems, Inc. Announces Events at SLEEP 2022, the 36th Annual Meeting of the Associated Professional Sleep Societies

Medical equipment producers suffered demand constrictions as Covid-19 hospital capacity and personnel were conscripted to handle the pandemic. INSP stock recuperated from $50 to $250 in a year. Today's MM-hedging induced price range forecast sees a 23%+ gain from shared current market price depression to return to the $185 base of its prior-year range.

Inspire Medical Systems Priced Low In Past-Year Repeated Range

MINNEAPOLIS, May 11, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will be presenting at the UBS Global Healthcare Conference on May 25, 2022 at the Lotte New York Palace in New York, New York.

Inspire Medical Systems, Inc. to Present at the USB Global Healthcare Conference 2022

Inspire Medical Systems, Inc. (NYSE:INSP ) Q1 2022 Results Conference Call May 3, 2022 5:00 PM ET Company Participants Megan Rowekamp - Investor Relations Timothy Herbert - President and Chief Executive Officer Richard Buchholz - Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities Robert Marcus - JPMorgan Chase Philip Coover - Goldman Sachs Group Danielle Antalffy - SVB Leerink Richard Newitter - Truist Securities Jonathan Block - Stifel, Nicolaus & Company Lei Huang - Wells Fargo Securities Adam Maeder - Piper Sandler & Co Michael Polark - Wolfe Research Suraj Kalia - Oppenheimer & Co Operator Good day and thank you for standing by. Welcome to the Inspire Medical Systems' Q1 2022 Financial Results and Business Update Conference Call.

News for Inspire Medical Systems Inc Stock (INSP)